Suppr超能文献

评估 N-乙酰半胱氨酸对预防和治疗认知老化和痴呆的神经保护潜力。

Evaluation of the Neuroprotective Potential of N-Acetylcysteine for Prevention and Treatment of Cognitive Aging and Dementia.

机构信息

Yuko Hara, PhD, Alzheimer's Drug Discovery Foundation, 57 West 57th St. Suite 904, New York, NY 10019, USA, Email:

出版信息

J Prev Alzheimers Dis. 2017;4(3):201-206. doi: 10.14283/jpad.2017.22.

Abstract

Alzheimer's disease is a progressive neurodegenerative disease for which there is no cure and only a few treatments providing little relief. Increased oxidative stress that is associated with aging is strongly implicated in the pathogenesis and progression of Alzheimer's disease. Studies have shown that levels of the endogenous antioxidant glutathione decline at an early stage of Alzheimer's disease with decreased levels correlating with worse cognitive functions. N-acetylcysteine, a drug also widely available as a dietary supplement, is a precursor of L-cysteine, which in turn is a component of glutathione. Because cysteine availability is a limiting factor for glutathione synthesis, treatment with N-acetylcysteine may increase glutathione levels and thereby counter oxidative stress, promote redox -regulated cell signaling, and improve immune responses. In this review, we evaluate the existing literature and the potential of N-acetylcysteine in promoting cognitive health and alleviating cognitive decline associated with dementia. Discussion will also include possible mechanisms of action of N-acetylcysteine, its effects on aging biology, and safety of long-term use. Based on the available literature, a nutraceutical formulation containing N-acetylcysteine among other compounds has shown some pro-cognitive benefits in Alzheimer's patients and older adults, but the evidence for N-acetylcysteine alone is less robust. Although N-acetylcysteine crosses the blood-brain-barrier, low bioavailability is an obstacle. One promising avenue of research may be to explore derivatives of N-acetylcysteine such as N-acetylcysteine amide, which has been reported in preclinical studies to have higher permeability through cellular and mitochondrial membranes with increased central nervous system bioavailability compared to N-acetylcysteine.

摘要

阿尔茨海默病是一种进行性神经退行性疾病,目前尚无治愈方法,仅有少数治疗方法能提供些许缓解。与衰老相关的氧化应激增加强烈提示了阿尔茨海默病的发病机制和进展。研究表明,内源性抗氧化剂谷胱甘肽的水平在阿尔茨海默病的早期阶段下降,水平降低与认知功能下降相关。N-乙酰半胱氨酸是一种广泛用作膳食补充剂的药物,它是 L-半胱氨酸的前体,而 L-半胱氨酸又是谷胱甘肽的组成部分。由于半胱氨酸的可用性是谷胱甘肽合成的限制因素,因此用 N-乙酰半胱氨酸治疗可能会增加谷胱甘肽水平,从而对抗氧化应激、促进氧化还原调节的细胞信号传递,并改善免疫反应。在这篇综述中,我们评估了现有的文献以及 N-乙酰半胱氨酸在促进认知健康和减轻与痴呆相关的认知能力下降方面的潜力。讨论还将包括 N-乙酰半胱氨酸的可能作用机制、它对衰老生物学的影响以及长期使用的安全性。根据现有文献,含有 N-乙酰半胱氨酸和其他化合物的营养配方在阿尔茨海默病患者和老年人中显示出一些认知益处,但单独使用 N-乙酰半胱氨酸的证据则不那么确凿。尽管 N-乙酰半胱氨酸可以穿过血脑屏障,但生物利用度低是一个障碍。一个有前途的研究方向可能是探索 N-乙酰半胱氨酸的衍生物,如 N-乙酰半胱氨酸酰胺,在临床前研究中已报道其穿过细胞和线粒体膜的通透性更高,与 N-乙酰半胱氨酸相比,中枢神经系统的生物利用度更高。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验